Dimension Therapeutics

About Dimension Therapeutics

Dimension Therapeutics was a clinical-stage biotechnology firm established in 2013, with its headquarters in Cambridge, Massachusetts. The company was formed through a collaboration between Fidelity Biosciences and REGENX Biosciences with the objective of developing novel treatments for rare diseases. Kenneth Mills is mentioned as a founder of the company. The company's scientific foundation was built upon the adeno-associated virus (AAV) vector technology developed by Dr. James Wilson at the University of Pennsylvania, which was licensed from REGENX. This technology was central to Dimension's strategy of creating gene therapies to deliver corrective genes to patient tissues.

The company's business was centered on discovering and developing therapeutic products for patients with rare and metabolic diseases linked to the liver. Its operational model involved identifying diseases with specific patient groups, reliable preclinical models, and validated biomarkers. Dimension's pipeline included programs for conditions such as ornithine transcarbamylase (OTC) deficiency, Glycogen Storage Disease Type Ia (GSDIa), and a collaboration with Bayer for hemophilia A. For instance, its product candidate DTX301 for OTC deficiency, which utilized an AAV8 vector, had entered a Phase 1/2 clinical trial. The business strategy included forming major partnerships, such as a significant licensing deal with Bayer to co-develop a treatment for hemophilia A, which provided Dimension with upfront payments and potential royalty streams.

In October 2017, after a bidding contest with REGENXBIO, Dimension Therapeutics entered into a definitive merger agreement with Ultragenyx Pharmaceutical Inc. Ultragenyx acquired all outstanding shares of Dimension for approximately $151 million in an all-cash transaction. The acquisition was completed in November 2017, at which point Dimension became a wholly-owned subsidiary of Ultragenyx, and its stock was delisted from the NASDAQ Global Select Market. This strategic acquisition allowed Ultragenyx to integrate Dimension's gene therapy platform and its early-stage clinical programs, while retaining Dimension's research and manufacturing teams in Massachusetts to leverage their expertise in the field.